The annual performance report of A-share listed companies is in full swing. Some companies can’t wait to release the performance forecast of the first quarter report of 2022, which has attracted the attention of many investors. Whose performance is better than expected, and who will explode the performance thunder? How to tap the investment opportunities
stock performance summary:
429 companies 2021 annual performance loss in advance
Statistics show that as of April 25, a total of 883 companies have issued performance forecasts for 2021. The types of performance forecasts show that 187 companies are expected to increase and 134 companies are expected to make profits, with a total positive reporting ratio of 36.35%, 127 companies are expected to reduce and 429 companies are expected to make losses.
According to the statistics of the industry, the expected loss companies in 2021 are mainly concentrated in the media, computer, medicine, biology and other industries, with 32, 32 and 30 companies on the list respectively.
Among the pre loss companies, 429 have announced the specific loss range. According to the statistics of the expected maximum loss, 81 shares have a loss of more than 1 billion yuan, the largest loss is Suning.Com Co.Ltd(002024) , and the company expects a loss of 42.3 billion yuan to 43.3 billion yuan in 2021. Others with large losses include China Fortune Land Development Co.Ltd(600340) , Jiangxi Zhengbang Technology Co.Ltd(002157) etc. China Fortune Land Development Co.Ltd(600340) is expected to lose 33.1 billion yuan to 39.1 billion yuan Jiangxi Zhengbang Technology Co.Ltd(002157) expected loss of 18.2 billion yuan to 19.7 billion yuan.
institutions, shareholders and executives scramble to buy these performance surge shares
From February 26 to April 25, among the dragon and tiger list, 447 individual stocks appeared in the figure of institutions, of which 176 stocks showed the status of net buying by institutions and 271 stocks were sold by institutions. There were eight stocks with a net purchase of more than 100 million yuan by institutions, and the top three were Yonghui Superstores Co.Ltd(601933) , Tech-Bank Food Co.Ltd(002124) , Andon Health Co.Ltd(002432) , and the net inflow of institutional funds was 381 million yuan, 370 million yuan and 267 million yuan respectively. Among the 327 stocks with significant growth (an increase of 50% or more) in 2021, 13 were net purchased by institutions from February 26 to April 25.
“ningwang” postponed the disclosure of quarterly report 14 million shareholders panicked! Doubled the performance of the first quarterly report
On April 24, Contemporary Amperex Technology Co.Limited(300750) issued an announcement. Based on the principle of prudence, in order to ensure the preparation quality of the first quarterly report and the accuracy of information disclosure, the disclosure time of the first quarterly report was postponed to April 30, and the original disclosure date of the company was April 28. As soon as the news came out, it immediately caused an uproar, and 140000 shareholders of the company were nervous.
First of all, regardless of the first quarterly report of Contemporary Amperex Technology Co.Limited(300750) , the performance of the company last year was indeed recognized by the capital market. In 2021, the company achieved a revenue of 130356 billion yuan, a year-on-year increase of 159.06%; The net profit was 15.931 billion yuan, a year-on-year increase of 185.34%; Among them, the net profit in the fourth quarter was nearly 8.2 billion yuan, setting a record high for single quarter performance. The largest performance source of the company is still power battery system, and the revenue of this business increased by 132% year-on-year; The revenue growth of the second lithium battery material and the third energy storage system was higher year-on-year, with 351% and 601% respectively.
In addition, the first quarterly report disclosed that it entered the sprint period. Statistics show that as of April 24, 761 listed companies have released the first quarter report or performance express of 2022. The net profit of 440 companies in the first quarter increased year-on-year, accounting for nearly 60%. Among them, the net profit of 113 companies doubled year-on-year; The net profit growth of 66 companies fell in the range of 50% – 100%.
surged 124 times month on month times Guangzhou Wondfo Biotech Co.Ltd(300482) the net profit in the first quarter exceeded that of last year! The performance of these companies fell
Benefiting from covid-19 testing business, Guangzhou Wondfo Biotech Co.Ltd(300482) handed over a beautiful “report card” in the first quarter. On April 24, Guangzhou Wondfo Biotech Co.Ltd(300482) disclosed the performance report for the first quarter of 2022, which showed that during the reporting period, the company achieved an operating revenue of 2.625 billion yuan, an increase of 276.87% over the same period of the previous year; The net profit attributable to shareholders of listed companies was 904 million yuan, an increase of 481.32% over the same period of last year; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 899 million yuan, an increase of 535.5% over the same period of last year.
In addition to Guangzhou Wondfo Biotech Co.Ltd(300482) , Andon Health Co.Ltd(002432) , Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) , Hangzhou Alltest Biotech Co.Ltd(688606) , Shenzhen Yhlo Biotech Co.Ltd(688575) , Guangdong Hybribio Biotech Co.Ltd(300639) and other covid-19 testing enterprises also achieved significant growth in the first quarter. For example, Andon Health Co.Ltd(002432) is expected to have a net profit of more than 14 billion yuan in the first quarter, with a maximum pre increase of 420 times
industry performance summary:
weekly report of textile and garment industry: optimistic performance outlook superimposed with good multiple profits continue to be optimistic about upstream manufacturing
We believe that the performance outlook of the middle and upper reaches of textile manufacturing 22q1 is optimistic. At the same time, there are many favorable factors in the near future, so we continue to focus on the recommendation; The short-term pressure of downstream brands still exists, and attention is paid to the long-term investment opportunities of sportswear. 1) Manufacturing side: continue to recommend the target with high Q1 performance. The prosperity of some enterprises at the upstream manufacturing end continues and the orders are full. It is expected that the performance of Q1 is expected to increase significantly. Since April, the overall order has been stable, superimposed with the recent favorable depreciation of RMB, and the performance growth of Q2 manufacturing end is expected to be sustainable. Recommendation Zhejiang Jasan Holding Group Co.Ltd(603558) : Q1 performance is expected to increase by more than 50%. Recommendation Huali Industrial Group Company Limited(300979) : lifting the ban may cause short-term pressure on capital, but the fundamentals are safe. Continue to be optimistic about the long-term growth of high-quality OEM leaders. Benefiting from Zhejiang Weixing Industrial Development Co.Ltd(002003) : Q1 zipper orders continue to grow beyond the industry, and the share is expected to continue to increase. 2) Brand side: pay attention to the long-term investment opportunities of sports leaders. Q1 affected by the epidemic, some brands such as FILA are under short-term pressure, but Anta and Tebu still perform well, and the operation indicators of each company remain good.
Since April, the epidemic situation is still very serious, and there is a high base for superimposed Q2. We expect that there is still pressure on the short-term brand side, but it is generally controllable, and 22h1 is expected to pass smoothly.
pharmaceutical and biological industry: focus on performance certainty and epidemic desensitization
Performance remains the core, focusing on the epidemic desensitization sector. Affected by multiple factors such as macroeconomic downward pressure and repeated outbreaks, the overall trading volume and amount of the pharmaceutical industry continued to shrink. Judging from the results of the annual report and the first quarter report released at present, some sectors of the pharmaceutical industry still show a steady growth trend. As covid-19 epidemic is still the main contradiction at present, in the short term, we still suggest paying attention to covid-19 related industrial chains, including covid-19 vaccine, covid-19 drug research and development progress, covid-19 testing industrial chain and other companies. In the medium term, we suggest to focus on the vaccine, CXO and the new medical infrastructure, medical services and consumer medical sectors that have sustained and steady growth.
weekly report of food and beverage industry: the performance intensive disclosure period is approaching optimistic about the continuous recovery of consumer confidence
Companies that are less affected by the epidemic this year and have lower cost certainty. Companies focusing on home consumption scenarios benefit from the epidemic, and their performance may be more elastic than expected due to the low base of q2-q3 last year. Moreover, the cost increase of some enterprises is relatively limited, or even decreased significantly. It is suggested to focus on: Chacha Food Company Limited(002557) , Chongqing Fuling Zhacai Group Co.Ltd(002507) , Henan Shuanghui Investment & Development Co.Ltd(000895) , Sanquan Food Co.Ltd(002216) .
Stocks with good long-term growth and current valuation has fallen to a low level. Under the influence of the epidemic, the performance of new consumer companies slowed down, killing both performance and valuation. However, it is only a short-term impact, and the long-term development drivers of the industry remain unchanged. It is suggested to pay attention to Shanghai Bairun Investment Holding Group Co.Ltd(002568) , Juewei Food Co.Ltd(603517) , Fu Jian Anjoy Foods Co.Ltd(603345) , etc.
nonferrous industry weekly report: industrial metal prices are under pressure and generally fall auto enterprises’ demand for resumption of lithium and cobalt production is expected to recover
The epidemic is still the biggest resistance to demand recovery, but under the requirements of the government to speed up the restoration of smooth logistics, the downstream demand is expected to improve, and the aluminum social inventory starts to go to the warehouse again; With the further mitigation of the impact of the epidemic, replenishment and resumption of production are expected to boost the demand and price of industrial metals. Meanwhile, the growth rate of infrastructure investment in the first quarter reached 10.5%, and the financial expenditure on urban and rural community affairs, agriculture, forestry and water affairs and transportation increased by 7.5%, 8.4% and 10.9% respectively. Infrastructure development is conducive to medium and long-term metal consumption.
In addition, driven by the policy, the automotive industry chain in Shanghai is returning to production in an orderly manner. With the gradual restoration of smooth logistics, the impact of the epidemic may weaken, and the demand for lithium and cobalt is expected to recover rapidly. It is recommended to pay attention to Tianqi Lithium Corporation(002466) , Ganfeng Lithium Co.Ltd(002460) , Zhejiang Huayou Cobalt Co.Ltd(603799) , Chengtun Mining Group Co.Ltd(600711) .
